Allogene Therapeutics to hold quarterly update on cell therapy progress

Allogene Therapeutics to hold quarterly update on cell therapy progress
Allogene sets Q1 2026 call

Allogene Therapeutics has announced it will hold its first quarter 2026 conference call on Wednesday, May 13 at 2:00 p.m. Pacific Time, equivalent to 5:00 p.m. Eastern Time.

The session is expected to include updates on the company’s CAR-T and cell therapy pipeline. Investors and stakeholders can learn more about participation and details through the company’s official channels.

Allogene recently launched ALLO-329, a new allogeneic CAR-T cell therapy targeting autoimmune diseases with Dagger technology, as detailed here. The company’s CTO, Ben Beneski, participated in an industry panel on advancing next-generation cell-based therapies at a leading event earlier this year. These initiatives highlight continued activity around cell therapy development.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.